Session Details
[S2]Radiopharmaceutical Sciences
Wed. Sep 17, 2025 3:00 PM - 4:30 PM JST
Wed. Sep 17, 2025 6:00 AM - 7:30 AM UTC
Wed. Sep 17, 2025 6:00 AM - 7:30 AM UTC
Hall S(Int’l)
[S2-07(Invited)]Development of At-211 YF2, a PSMA-targeted agent: from bench to bedside, and academia to industry
*Yutian Feng Feng1 (1. Duke University Medical Center (United States of America))
[S2-08]Production of 211At/18F-labeled PSMA compounds for radiotheranostics under Investigational GMP
*Sadahiro Naka1,2, Yoshifumi Shirakami3, Kazuhiro Ooe3, Kenta Kurimoto1,2, Toshihiro Sakai1, Masashi Murakami3, Yukiyoshi Kon3, Hiromitsu Haba4, Atsushi Toyoshima3, Tadashi Watabe1,3, Noriyuki Tomiyama1,3 (1. Department of Radiology, Graduate School of Medicine, The University of Osaka (Japan), 2. Department of Pharmacy, The University of Osaka Hospital (Japan), 3. Institute for Radiation Sciences, The University of Osaka (Japan), 4. Nishina Center for Accelerator-Based Science, RIKEN (Japan))
[S2-09*]Astatine dry distillation: evaluating co-distillation of radionuclidic impurities and target starting material.
*Ellinor Hansson1,2, Charlotte Ytterbrink1, Tom Bäck1, Erik Leidermark1,4, Holger Jensen3, Björn Eriksson2, Sture Lindegren1, Emma Aneheim1,4 (1. Gothenburg University (Sweden), 2. Atley Solutions (Sweden), 3. Copenhagen University Hospital (Denmark), 4. Sahlgrenska University Hospital (Sweden))
[S2-10*]Neutron activation of gold nanoparticles for imaging of pharmacokinetics
*Nanase Koshikawa1, Yuka Kikuchi1, Jun Kataoka1, Kazuo Skipjack Tanaka1, Katsuyuki Tokoi2, Akina Mitsukai2, Hiroki Aoto2, Masashi Murakami2, Yuichiro Kadonaga2, Atsushi Toyoshima2, Hiroki Kato2, Kazuhiro Ooe2, Koichi Takamiya3 (1. Waseda Univ. (Japan), 2. Osaka Univ. (Japan), 3. Kyoto Univ. (Japan))